VT Co., Ltd. (KOSDAQ:018290)

Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Other Revenue	-0	-0	-	-	-	-
Revenue	430,346	431,697	295,501	240,241	226,770	107,395
Revenue Growth (YoY)	23.16%	46.09%	23.00%	5.94%	111.15%	-4.75%
Cost of Revenue	179,714	192,938	155,762	135,431	131,647	74,012
Gross Profit	250,632	238,758	139,739	104,811	95,122	33,384
Selling, General & Admin	130,676	124,353	89,884	75,840	62,586	24,898
Research & Development	1,039	692.1	181.33	1,560	2,429	1,824
Operating Expenses	134,727	127,904	94,440	81,427	69,507	27,909
Operating Income	115,905	110,855	45,299	23,384	25,615	5,474
Interest Expense	-2,258	-2,111	-1,742	-2,975	-4,544	-2,788
Interest & Investment Income	2,204	1,685	1,620	432.35	181.6	142.98
Earnings From Equity Investments	-	-	-	-751.59	-415.11	-519.02
Currency Exchange Gain (Loss)	3,220	2,012	-1,014	-1,785	520.04	-547.07
Other Non Operating Income (Expenses)	321.62	195.3	-692.53	32.85	1,110	-169.59
EBT Excluding Unusual Items	119,392	112,636	43,471	18,337	22,467	1,593
Gain (Loss) on Sale of Investments	22,075	21,422	-525.7	-1,246	1,615	-2,670
Gain (Loss) on Sale of Assets	-44.69	46.6	58.18	-9.17	772.99	17.71
Asset Writedown	-16.13	-16.13	-1,543	-3,291	-3,235	-
Other Unusual Items	-	-	59.44	-	-	-
Pretax Income	141,407	134,089	41,520	13,790	21,621	-1,059
Income Tax Expense	32,432	30,090	9,830	585.28	4,123	249.44
Earnings From Continuing Operations	108,975	103,999	31,690	13,205	17,498	-1,309
Minority Interest in Earnings	-4,674	-5,955	-4,422	-2,055	-2,584	2,414
Net Income	104,301	98,044	27,268	11,149	14,914	1,105
Net Income to Common	104,301	98,044	27,268	11,149	14,914	1,105
Net Income Growth	146.40%	259.55%	144.57%	-25.24%	1249.18%	-61.00%
Shares Outstanding (Basic)	35	36	34	33	33	32
Shares Outstanding (Diluted)	35	36	34	33	33	32
Shares Change (YoY)	1.91%	4.02%	4.56%	-0.09%	1.84%	17.10%
EPS (Basic)	2938.68	2761.24	798.86	341.52	456.43	34.45
EPS (Diluted)	2938.40	2761.00	798.86	341.52	456.00	34.00
EPS Growth	141.76%	245.62%	133.91%	-25.11%	1241.18%	-66.99%
Free Cash Flow	76,439	83,546	24,509	52,055	46,772	-5,233
Free Cash Flow Per Share	2153.67	2352.93	718.02	1594.50	1431.42	-163.10
Gross Margin	58.24%	55.31%	47.29%	43.63%	41.95%	31.09%
Operating Margin	26.93%	25.68%	15.33%	9.73%	11.30%	5.10%
Profit Margin	24.24%	22.71%	9.23%	4.64%	6.58%	1.03%
Free Cash Flow Margin	17.76%	19.35%	8.29%	21.67%	20.63%	-4.87%
EBITDA	121,810	117,111	53,647	31,625	33,599	7,884
EBITDA Margin	28.31%	27.13%	18.15%	13.16%	14.82%	7.34%
D&A For EBITDA	5,905	6,256	8,348	8,242	7,983	2,410
EBIT	115,905	110,855	45,299	23,384	25,615	5,474
EBIT Margin	26.93%	25.68%	15.33%	9.73%	11.30%	5.10%
Effective Tax Rate	22.93%	22.44%	23.67%	4.24%	19.07%	-
Advertising Expenses	-	26,628	20,608	17,743	20,296	3,677

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.